Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single-Center, Proof-of-Concept Safety and Efficacy Study of Orally Administered OLT1177 Capsules with Successive, Result-Dependent Dose Adaptation in Subjects with an Acute Gout Flare

Next Previous
X
Search
Trial Profile

A Phase 2 Single-Center, Proof-of-Concept Safety and Efficacy Study of Orally Administered OLT1177 Capsules with Successive, Result-Dependent Dose Adaptation in Subjects with an Acute Gout Flare

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapansutrile (Primary)
  • Indications Gout
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Olatec Therapeutics

    • Most Recent Events

    • 27 Oct 2020 According to an Olatec Therapeutics media release, clinical trial data from this study were published in The Lancet Rheumatology.
    • 11 May 2020 According to an Olatec Therapeutics Media Release, the company was the main funder of the trial, along with the National Institutes of Health and The Interleukin Foundation.
    • 11 May 2020 Results published in the Olatec Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top